Clinical Edge

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Azithromycin prevents airway complications of antibody deficiency

Key clinical point: Low-dose azithromycin prophylaxis reduces exacerbations and other respiratory events in primary airway deficiency.

Major finding: Relative to placebo over 2 years, low-dose azithromycin significantly reduced the annual rate of exacerbations by 1.6 episodes per patient.

Data Source: Phase 2 multicenter, placebo-controlled trial.

Disclosures: Dr. Milito reported no potential conflicts of interest.

Citation:

ERS 2019; Milito C et al. J Allergy Clin Immunol 2019;144: 584-593